Literature DB >> 20010842

Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemia.

Tomasz Cierpicki1, Laurie E Risner, Jolanta Grembecka, Stephen M Lukasik, Relja Popovic, Monika Omonkowska, David D Shultis, Nancy J Zeleznik-Le, John H Bushweller.   

Abstract

The gene MLL (encoding the protein mixed-lineage leukemia) is the target of chromosomal translocations that cause leukemias with poor prognosis. All leukemogenic MLL fusion proteins retain the CXXC domain, which binds to nonmethylated CpG DNA sites. We present the solution structure of the MLL CXXC domain in complex with DNA, showing how the CXXC domain distinguishes nonmethylated from methylated CpG DNA. On the basis of the structure, we generated point mutations that disrupt DNA binding. Introduction of these mutations into the MLL-AF9 fusion protein resulted in increased DNA methylation of specific CpG nucleotides in Hoxa9, increased H3K9 methylation, decreased expression of Hoxa9-locus transcripts, loss of immortalization potential, and inability to induce leukemia in mice. These results establish that DNA binding by the CXXC domain and protection against DNA methylation is essential for MLL fusion leukemia. They also provide support for viewing this interaction as a potential target for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20010842      PMCID: PMC2908503          DOI: 10.1038/nsmb.1714

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN: 1545-9985            Impact factor:   15.369


  42 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation.

Authors:  Marco Birke; Silke Schreiner; María-Paz García-Cuéllar; Kerstin Mahr; Fritz Titgemeyer; Robert K Slany
Journal:  Nucleic Acids Res       Date:  2002-02-15       Impact factor: 16.971

3.  Identification and characterization of the DNA binding domain of CpG-binding protein.

Authors:  J H Lee; K S Voo; D G Skalnik
Journal:  J Biol Chem       Date:  2001-09-25       Impact factor: 5.157

4.  Solution structure of the methyl-CpG binding domain of human MBD1 in complex with methylated DNA.

Authors:  I Ohki; N Shimotake; N Fujita; J Jee; T Ikegami; M Nakao; M Shirakawa
Journal:  Cell       Date:  2001-05-18       Impact factor: 41.582

Review 5.  Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer.

Authors:  S B Baylin; M Esteller; M R Rountree; K E Bachman; K Schuebel; J G Herman
Journal:  Hum Mol Genet       Date:  2001-04       Impact factor: 6.150

6.  Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia.

Authors:  C Lavau; C Du; M Thirman; N Zeleznik-Le
Journal:  EMBO J       Date:  2000-09-01       Impact factor: 11.598

7.  Quantitative NMR studies of high molecular weight proteins: application to domain orientation and ligand binding in the 723 residue enzyme malate synthase G.

Authors:  Vitali Tugarinov; Lewis E Kay
Journal:  J Mol Biol       Date:  2003-04-11       Impact factor: 5.469

8.  Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients.

Authors:  M Christina Cox; Paola Panetta; Francesco Lo-Coco; Giovanni Del Poeta; Adriano Venditti; Luca Maurillo; M Ilaria Del Principe; Alessandro Mauriello; Lucia Anemona; Antonio Bruno; Carla Mazzone; Paolo Palombo; Sergio Amadori
Journal:  Am J Clin Pathol       Date:  2004-08       Impact factor: 2.493

9.  Mbd1 is recruited to both methylated and nonmethylated CpGs via distinct DNA binding domains.

Authors:  Helle F Jørgensen; Ittai Ben-Porath; Adrian P Bird
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

10.  MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein.

Authors:  Zhen-Biao Xia; Melanie Anderson; Manuel O Diaz; Nancy J Zeleznik-Le
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-26       Impact factor: 11.205

View more
  89 in total

1.  Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia.

Authors:  Laurie E Risner; Aravinda Kuntimaddi; Alyson A Lokken; Nicholas J Achille; Noah W Birch; Kelly Schoenfelt; John H Bushweller; Nancy J Zeleznik-Le
Journal:  J Biol Chem       Date:  2013-08-29       Impact factor: 5.157

Review 2.  TET family proteins: new players in gliomas.

Authors:  Er-Bao Bian; Gang Zong; Yong-Sheng Xie; Xiao-Ming Meng; Cheng Huang; Jun Li; Bing Zhao
Journal:  J Neurooncol       Date:  2014-01-07       Impact factor: 4.130

3.  The mysterious presence of a 5-methylcytosine oxidase in the Drosophila genome: possible explanations.

Authors:  Thomas L Dunwell; Liam J McGuffin; Jim M Dunwell; Gerd P Pfeifer
Journal:  Cell Cycle       Date:  2013-09-19       Impact factor: 4.534

4.  Not All H3K4 Methylations Are Created Equal: Mll2/COMPASS Dependency in Primordial Germ Cell Specification.

Authors:  Deqing Hu; Xin Gao; Kaixiang Cao; Marc A Morgan; Gloria Mas; Edwin R Smith; Andrew G Volk; Elizabeth T Bartom; John D Crispino; Luciano Di Croce; Ali Shilatifard
Journal:  Mol Cell       Date:  2017-02-02       Impact factor: 17.970

Review 5.  The pathogenesis of mixed-lineage leukemia.

Authors:  Andrew G Muntean; Jay L Hess
Journal:  Annu Rev Pathol       Date:  2011-10-17       Impact factor: 23.472

6.  Crystal structure of the N-terminal region of human Ash2L shows a winged-helix motif involved in DNA binding.

Authors:  Yong Chen; Bingbing Wan; Kevin C Wang; Fang Cao; Yuting Yang; Angeline Protacio; Yali Dou; Howard Y Chang; Ming Lei
Journal:  EMBO Rep       Date:  2011-06-10       Impact factor: 8.807

7.  MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome.

Authors:  Qian-Fei Wang; George Wu; Shuangli Mi; Fuhong He; Jun Wu; Jingfang Dong; Roger T Luo; Ryan Mattison; Joseph J Kaberlein; Shyam Prabhakar; Hongkai Ji; Michael J Thirman
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

8.  Selective targeting of histone methylation.

Authors:  Abul B M M K Islam; William F Richter; Nuria Lopez-Bigas; Elizaveta V Benevolenskaya
Journal:  Cell Cycle       Date:  2011-02-01       Impact factor: 4.534

Review 9.  Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.

Authors:  Bin E Li; Patricia Ernst
Journal:  Exp Hematol       Date:  2014-09-28       Impact factor: 3.084

10.  Transient resistance to DNA damaging agents is associated with expression of microRNAs-135b and -196b in human leukemia cell lines.

Authors:  Tsui-Ting Ho; Xiaolong He; Yin-Yuan Mo; William T Beck
Journal:  Int J Biochem Mol Biol       Date:  2016-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.